Dianthus Therapeutics
(NASDAQ) DNTH
Dianthus Therapeutics Financials at a Glance
Market Cap
$5.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$1.34M
Net Income (TTM)
-$11.32M
EPS (TTM)
-$4.14
P/E Ratio
-22.55
Dividend
$0.00
Beta (Volatility)
1.05 (Average)
Dividend
$0.00
Beta (Volatility)
1.05 (Average)
Price
$95.75
Volume
31,929
Open
$93.39
Price
$95.75
Volume
31,929
Open
$93.39
Previous Close
$95.75
Daily Range
$92.54 - $96.75
52-Week Range
$18.08 - $98.70
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.05 (Average)
Price
$95.75
Volume
31,929
Open
$93.39
Previous Close
$95.75
Daily Range
$92.54 - $96.75
52-Week Range
$18.08 - $98.70
Estimated Earnings Date
Aug 6, 2026
DNTH News
DNTH: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Dianthus Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
92
CEO
Marino Garcia, MBA
Website
dianthustx.comHeadquarters
New York, NY 10036, US
DNTH Financials
Key Financial Metrics (TTM)
Gross Margin
94.31%
Operating Margin
-14318.04%
Net Income Margin
-847.53%
Return on Equity
-1.78%
Return on Capital
-35.96%
Return on Assets
-0.91%
Earnings Yield
-4.43%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$5.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
54.67M
Volume
31.93K
Avg. Volume
895.69K
Financials (TTM)
Gross Profit
$1.26M
Operating Income
-$191.29M
EBITDA
-$10.86M
Operating Cash Flow
-$130.29M
Capital Expenditure
-$199.00K
Free Cash Flow
-$130.49M
Cash & ST Invst.
$1.11B
Total Debt
$1.36M
Dianthus Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$463.00K
-60.2%
Gross Profit
$387.00K
-66.7%
Gross Margin
83.59%
N/A
Market Cap
$5.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$55.46M
N/A
Employees
92
N/A
Net Income
-$40.83M
-38.4%
EBITDA
-$40.76M
-38.7%
Quarterly Fundamentals
Total Cash
$1.11B
+322.2%
Total Debt
$1.36M
-2.3%
Accounts Receivable
$1.23M
+23.0%
Inventory
$0.00
N/A
Long Term Debt
$965.00K
-17.5%
Short Term Debt
$399.00K
+76.5%
Return on Assets
-0.91%
N/A
Return on Invested Capital
-15.83%
N/A
Free Cash Flow
-$28.87M
-4.4%
Operating Cash Flow
-$28.86M
-4.4%